Check for updates

## scientific reports

Published online: 21 July 2021

## **OPEN** Author Correction: Strictly regulated agonist-dependent activation of AMPA-R is the key characteristic of TAK-653 for robust synaptic responses and cognitive improvement

Atsushi Suzuki, Akiyoshi Kunuqi, Yasukazu Tajima, Noriko Suzuki, Motohisa Suzuki, Masashi Toyofuku, Haruhiko Kuno, Satoshi Sogabe, Yohei Kosugi, Yasuyuki Awasaki, Tomohiro Kaku & Haruhide Kimura

Correction to: Scientific Reports https://doi.org/10.1038/s41598-021-93888-0, published online 15 July 2021

The original version of this Article contained an error in Figures 3 and 5 where the y-axis did not display correctly in panel B. The original Figures 3 and 5 and their accompanying legends appear below.

The original Article has been corrected.



**Figure 3.** Effects of TAK-653 on BDNF expression in vitro and in vivo. (**A**) Effects of TAK-653 on BDNF protein levels in rat primary hippocampal neurons. Cells were treated with AMPA (0 or 1  $\mu$ M) and TAK-653 (0.01, 0.1, 1  $\mu$ M) for 24 h and then were collected using lysis buffer. Cells in control group were treated with 1  $\mu$ M AMPA and DMSO. Values were expressed as pg per mL. Data are represented as mean ± SD (n = 3). Statistical significance was determined by a two-tailed Williams' test with significance set at  ${}^{#}P \le 0.05$  (versus control group; two-tailed Williams' test). (**B**) Effects of TAK-653 on BDNF mRNA in hippocampus in AMPA (3.5 mg/kg, i.v.)-treated mice. TAK-653 (3 and 10 mg/kg, p.o.) was administered to mice 1 h before the administration of AMPA (3.5 mg/kg, i.v.) (left) or vehicle (right). Tissues were isolated 3 h after AMPA administration. Data were presented as the mean ± SEM (n = 23–24).  ${}^{#}P \le 0.05$  (versus vehicle-treated group; two-tailed Williams' test).

Scientific Reports | (2021) 11:15255 |



**Figure 5.** Effects of repeated treatment of TAK-653 on AMPA-induced BDNF (**A**) or Gadd45b (**B**) mRNA expression in mouse hippocampus. Vehicle or TAK-653 (0.3 mg/kg, p.o.) for 14 days were administered to mice. On the day 14, vehicle or AMPA (1.25, 2.5, 5 or 10 mg/kg, i.v.) was administered 1 h after vehicle (left) or TAK-653 (right). Tissues were isolated 3 h after AMPA administration. Data were presented as the mean  $\pm$  SEM (n=23-24). \**P* ≤ 0.05 (versus vehicle-treated group; two-tailed Shirley–Williams test).

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021